Emergent BioSolutions (EBS) Misses Q4 EPS by 35c; Offers FY23 Revenue Guidance
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $6.80 -3.13%
EPS Growth %: -138.7%
Financial Fact:
Selling, general and administrative: 40.69M
Today's EPS Names:
VIVO, OCCI, ALZN, More
EPS Growth %: -138.7%
Financial Fact:
Selling, general and administrative: 40.69M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q4 EPS of ($0.31), $0.35 worse than the analyst estimate of $0.04. Revenue for the quarter came in at $331 million versus the consensus estimate of $297.18 million.
GUIDANCE:
Emergent BioSolutions sees FY2023 revenue of $1.15 billion, versus the consensus of $1.18 billion.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westinghouse said to seek over $50 billion valuation in planned IPO
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Kestra Medical Technologies, Ltd. (KMTS) Reports Q1 Loss of $0.75/sh
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
